As GLP-1s are becoming more commonly prescribed for obesity and other health conditions by providers across multiple disciplines, there is growing concern for the continued lack of formal medical training in nutrition and obesity and paucity of basic knowledge and competencies to provide nutrition counseling [103,104]
So much so, in fact, that Congress is considering legislation that would partly lift the two-decade prohibition on Medicare coverage of AOMs
Diabetes 53 , 654662 (2004)
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
The Problem We Solve: Dont let side effects hold you back from reaching your health goals
Development Updates on Danuglipron However, due to potential liver toxicity effects, Pfizer, the developer of danuglipron, has discontinued its efforts to license the drug candidate